All In Biotech

Drug Trial Radar · NCT01444430

A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents

A 26 Week, Randomized, Double-blind, Parallel-group, Active Controlled, Multicenter, Multinational Safety Study Evaluating the Risk of Serious Asthma-related Events During Treatment With Symbicort®, a Fixed Combination of Inhaled Corticosteroid (ICS) (Budesonide) and a Long Acting β2-agonist (LABA) (Formoterol) as Compared to Treatment With ICS (Budesonide) Alone in Adult and Adolescent (≥12 Years of Age) Patients With Asthma

Last checked: Nov 19, 2026Latest source record: Dec 15, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 12,460 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

12,460

Actual

Start

Dec 2011

Primary completion

Oct 2015

Study completion Oct 2015

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Sep 30, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the safety of Symbicort compared to inhaled corticosteroid alone during 6 months in adult and adolescent patients with asthma

Conditions

  • Asthma

Interventions

  • Symbicort pMDIDrug

    Patients were randomized to Symbicort and assigned to one of the following treatments (based upon ACQ at baseline and prior asthma therapy): Symbicort pMDI 80/4.5 μg x 2 actuations bid (morning and evening) or Symbicort pMDI 160/4.5 μg x 2 actuations bid (morning and evening), for oral inhalation.

  • budesonide pMDIDrug

    Patients were randomized to budesonide and assigned to one of the following treatments (based upon ACQ at baseline and prior asthma therapy): budesonide pMDI 80 μg x 2 actuations bid (morning and evening) or budesonide pMDI 160 μg x 2 actuations bid (morning and evening), for oral inhalation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing an Event in the Composite Endpoint (Asthma-related Death, Asthma-related Intubation or Asthma-related Hospitalization)Time frame: Up to 27 weeks
  2. Number of Participants Experiencing an Event Included in the Definition of Asthma ExacerbationTime frame: Up to 26 weeks

Locations

340 sites in 26 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Huntsville, Alabama

  • Research Site

    Anchorage, Alaska

  • Research Site

    Gilbert, Arizona

  • Research Site

    Glendale, Arizona

  • Research Site

    Mesa, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Fort Smith, Arkansas

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Alhambra, California

  • Research Site

    Anaheim, California

  • Research Site

    Arvin, California

  • Research Site

    Bellflower, California

  • Research Site

    Buena Park, California

  • Research Site

    Costa Mesa, California

  • Research Site

    Encinitas, California

  • Research Site

    Escondido, California

  • Research Site

    Fountain Valley, California

  • Research Site

    Glendale, California

  • Research Site

    Long Beach, California

  • Research Site

    Los Angeles, California

  • Research Site

    Newport Beach, California

  • Research Site

    Northridge, California

  • Research Site

    Palmdale, California

  • Research Site

    Pasadena, California

  • Research Site

    Poway, California

  • Research Site

    Riverside, California

  • Research Site

    Roseville, California

  • Research Site

    San Diego, California

  • Research Site

    San Jose, California

  • Research Site

    Santa Ana, California

  • Research Site

    Stockton, California

  • Research Site

    Tustin, California

  • Research Site

    Walnut Creek, California

  • Research Site

    Denver, Colorado

  • Research Site

    Thornton, Colorado

  • Research Site

    Norwalk, Connecticut

  • Research Site

    Waterbury, Connecticut

  • Research Site

    Altamonte Springs, Florida

  • Research Site

    Clearwater, Florida

Showing 40 of 340 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.